Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunotherapy
|
| gptkbp:administeredBy |
gptkb:Injection
Patients with advanced cancer Patients with refractory cancer Patients with relapsed cancer |
| gptkbp:alternativeName |
DC therapy
Dendritic cell vaccine Dendritic cell-based immunotherapy |
| gptkbp:approvedBy |
2010
Provenge (sipuleucel-T) for prostate cancer |
| gptkbp:category |
Personalized medicine
Cell therapy |
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
Phase II Phase III |
| gptkbp:developedBy |
1990s
|
| gptkbp:firstApprovedCountry |
gptkb:United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dendritic Cell Therapy
|
| gptkbp:involves |
Dendritic cells
|
| gptkbp:mechanismOfAction |
Activation of immune response
|
| gptkbp:NobelPrizeYear |
Ralph Steinman, Nobel Prize in Physiology or Medicine 2011
|
| gptkbp:notableContributor |
gptkb:Ralph_Steinman
|
| gptkbp:notableProduct |
gptkb:Provenge
|
| gptkbp:regulates |
T cell activation
Antigen presentation FDA approved for prostate cancer Investigational for other cancers |
| gptkbp:relatedTo |
gene therapy
Adoptive cell therapy Cancer vaccine Immune checkpoint inhibitor |
| gptkbp:requires |
Quality control
Antigen loading Ex vivo cell culture Leukapheresis |
| gptkbp:sideEffect |
Fever
Fatigue Chills Injection site reaction |
| gptkbp:studiedBy |
gptkb:Melanoma
gptkb:Glioblastoma gptkb:Renal_cell_carcinoma gptkb:HIV Multiple sclerosis Rheumatoid arthritis Breast cancer Hepatocellular carcinoma Ovarian cancer |
| gptkbp:usedFor |
Cancer treatment
Autoimmune disease treatment |
| gptkbp:bfsParent |
gptkb:Cell_Therapy
|
| gptkbp:bfsLayer |
6
|